TELA Bio to Participate in Upcoming JMP Securities Life Sciences Conference
Get Alerts TELA Hot Sheet
Join SI Premium – FREE
MALVERN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that the Company will participate in the JMP Securities Life Sciences Conference on June 16th, 2022.
TELA Bio’s management is scheduled to present at the JMP Securities Life Sciences Conference on Thursday, June 16th, 2022, at 11:00am ET. Interested parties can access the live and archived webcast at ir.telabio.com.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Investor ContactGreg Chodaczek332-895-3230[email protected]
Source: TELA Bio, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pet Valu Serves up a Purr-fect New Recipe for Mealtime: Performatrin® Culinary for Cats
- Presenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live stream
- Asimov Announces Cell Line Development Partnership with Kaigene to Advance Multispecific Antibody for Autoimmune Disease
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share